WO1993020099A3 - Cck and/or gastrin receptor ligands - Google Patents

Cck and/or gastrin receptor ligands Download PDF

Info

Publication number
WO1993020099A3
WO1993020099A3 PCT/GB1993/000614 GB9300614W WO9320099A3 WO 1993020099 A3 WO1993020099 A3 WO 1993020099A3 GB 9300614 W GB9300614 W GB 9300614W WO 9320099 A3 WO9320099 A3 WO 9320099A3
Authority
WO
WIPO (PCT)
Prior art keywords
cck
compounds
treatment
receptor ligands
medicinal compositions
Prior art date
Application number
PCT/GB1993/000614
Other languages
French (fr)
Other versions
WO1993020099A2 (en
Inventor
Hamish Ryder
David Alan Kendrick
Graeme Semple
Keiji Miyata
Andrzej Roman Batt
Elizabeth Alice Mathews
David Philip Rooker
Akito Nishida
Original Assignee
Ferring Bv
Yamanouchi Pharma Co Ltd
Hamish Ryder
David Alan Kendrick
Graeme Semple
Keiji Miyata
Andrzej Roman Batt
Elizabeth Alice Mathews
David Philip Rooker
Akito Nishida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv, Yamanouchi Pharma Co Ltd, Hamish Ryder, David Alan Kendrick, Graeme Semple, Keiji Miyata, Andrzej Roman Batt, Elizabeth Alice Mathews, David Philip Rooker, Akito Nishida filed Critical Ferring Bv
Publication of WO1993020099A2 publication Critical patent/WO1993020099A2/en
Publication of WO1993020099A3 publication Critical patent/WO1993020099A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06156—Dipeptides with the first amino acid being heterocyclic and Trp-amino acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

This invention relates to novel compounds with the general structure A-B-C and their pharmaceutically acceptable salts, to medicinal compositions containing them, and to the use of such medicinal compositions in the treatment of certain disease states. The compounds of the invention are represented schematically as A-B-C wherein S1-S4 are in general lypophilic residues, S5 is a polar or hydrophilic residue, and L1-L5 are optional linking units. The compounds of this invention bind to CCK and/or gastrin receptors with high affinity and are therefore useful in the treatment of diseases which involve the dysfunction of a physiological process regulated by either of these hormones.
PCT/GB1993/000614 1992-03-27 1993-03-25 Cck and/or gastrin receptor ligands WO1993020099A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9206757.8 1992-03-27
GB929206757A GB9206757D0 (en) 1992-03-27 1992-03-27 Novel peptide receptor ligands

Publications (2)

Publication Number Publication Date
WO1993020099A2 WO1993020099A2 (en) 1993-10-14
WO1993020099A3 true WO1993020099A3 (en) 1993-11-25

Family

ID=10712996

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1993/000614 WO1993020099A2 (en) 1992-03-27 1993-03-25 Cck and/or gastrin receptor ligands

Country Status (3)

Country Link
AU (1) AU3764593A (en)
GB (1) GB9206757D0 (en)
WO (1) WO1993020099A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107922428A (en) * 2015-06-25 2018-04-17 普洛麦格公司 Thienopyrroles compound and its purposes as the inhibitor for piercing shrimp source property luciferase

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0720601B1 (en) * 1993-08-10 2000-10-25 James Black Foundation Limited Gastrin and cck receptor ligands
US5795907A (en) * 1994-05-27 1998-08-18 James Black Foundation Limited Gastin and CCK receptor ligands
WO1996039385A1 (en) 1995-06-06 1996-12-12 Pfizer Inc. Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors
KR100241643B1 (en) 1995-06-06 2000-03-02 디. 제이. 우드 Substituted N- (indole-2-carbonyl) -β-alanimamide and its derivatives for treating diabetes
MX9709875A (en) * 1995-06-06 1998-03-31 Pfizer Substituted n-(indole-2-carbonyl)-glycinamides and derivatives as glycogen phosphorylase inhibitors.
GB9610974D0 (en) * 1996-05-24 1996-07-31 Zeneca Ltd Herbicides
GB9708805D0 (en) 1997-05-01 1997-06-25 Smithkline Beecham Plc Compounds
TW527355B (en) 1997-07-02 2003-04-11 Bristol Myers Squibb Co Inhibitors of farnesyl protein transferase
PT1042288E (en) * 1997-12-23 2008-03-11 Bioprojet Soc Civ Tripeptidyl peptidase inhibitors
US5955471A (en) * 1998-01-13 1999-09-21 Sk Corporation Tetrahydroisoquinolinealkanol derivatives and pharmaceutical compositions containing same
GB9810876D0 (en) 1998-05-20 1998-07-22 Smithkline Beecham Plc Compounds
WO1999062514A1 (en) * 1998-06-03 1999-12-09 Cortech Inc. INDOLE AND TETRAHYDROISOQUINOLINE CONTAINING α-KETO OXADIAZOLES AS SERINE PROTEASE INHIBITORS
EP1114822A3 (en) * 1998-06-03 2002-11-13 Cortech Inc. Indoles and tetrahydroisoquinolines containing alpha-keto oxadiazoles as serine protease inhibitors
ID28385A (en) 1998-10-08 2001-05-17 Smithkline Beecham Plc TETRAHIDROBENZAZEPINA DECREASED USING AS DOPAMINA D3 RECEPTOR MODULATOR (ANTIPSICOTIC MATERIAL)
US6331541B1 (en) 1998-12-18 2001-12-18 Soo S. Ko N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
US6525069B1 (en) 1998-12-18 2003-02-25 Bristol-Myers Squibb Pharma Co. N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
US6444686B1 (en) 1998-12-18 2002-09-03 Brsitol-Myers Squibb Pharma Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
DE69926919D1 (en) 1998-12-18 2005-09-29 Bristol Myers Squibb Pharma Co N-UREIDOALKYLPIPERIDINES AS MODULATORS OF THE ACTIVITY OF CHEMOKIN RECEPTORS
US6331545B1 (en) 1998-12-18 2001-12-18 Soo S. Ko Heterocycyclic piperidines as modulators of chemokine receptor activity
US6897234B2 (en) 1999-12-17 2005-05-24 Bristol-Myers Squibb Pharma Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
SE0000382D0 (en) 2000-02-07 2000-02-07 Astrazeneca Ab New process
DE60115227T2 (en) 2000-05-11 2006-08-24 Bristol-Myers Squibb Co. TETRAHYDROISOCHINOLINE ANALOGUE AS GROWTH HORMONE SECRETAGOGA
IL153123A0 (en) 2000-06-30 2003-06-24 Bristol Myers Squibb Co N-ureidoheterocycloalkyl-piperidine derivatives and pharmaceutical compositions containing the same
US6277877B1 (en) 2000-08-15 2001-08-21 Pfizer, Inc. Substituted n-(indole-2-carbonyl)glycinamides and derivates as glycogen phosphorylase inhibitors
AU2002357692A1 (en) 2001-11-09 2003-05-26 Bristol-Myers Squibb Company Tetrahydroisoquinoline analogs as modulators of chemokine receptor activity
AU2003245453B2 (en) 2002-06-14 2008-08-14 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
CA2486215A1 (en) 2002-06-14 2003-12-24 Merck & Co., Inc. Mitotic kinesin inhibitors
DE602004019229D1 (en) 2003-08-15 2009-03-12 Merck & Co Inc INHIBITORS OF MITOTIC KINESINE
WO2005018547A2 (en) 2003-08-15 2005-03-03 Merck & Co., Inc. Mitotic kinesin inhibitors
US7638549B2 (en) 2003-08-15 2009-12-29 Merck & Co. Inc. Mitotic kinesin inhibitors
FR2876102A1 (en) * 2004-10-04 2006-04-07 Solvay ENANTIOPUR HETEROCYCLIC COMPOUND
JP5121346B2 (en) * 2007-08-07 2013-01-16 国立大学法人 長崎大学 Optically active proline ester derivative and method for producing N-formyl optically active proline derivative
BR112012018374B1 (en) 2009-12-18 2021-09-21 Epics Therapeutics PYRROLIDINE OR THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES FOR METABOLIC DISORDERS AS G-PROTEIN G-PROTEIN AGONISTS (GPR43), ITS PREPARATION PROCESS AND PHARMACEUTICAL COMPOSITION
US9085555B2 (en) 2011-01-04 2015-07-21 Novartis Ag Complement pathway modulators and uses thereof
CN103987697B (en) 2011-10-14 2017-04-26 百时美施贵宝公司 Substituted tetrahydroisoquinoline compounds as factor XIA inhibitors
PE20141825A1 (en) 2011-10-14 2014-11-29 Bristol Myers Squibb Co TETRAHYDROISOQUINOLINE COMPOUNDS SUBSTITUTED AS INHIBITORS OF THE XIA FACTOR
JP6033318B2 (en) 2011-10-14 2016-11-30 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Substituted tetrahydroisoquinoline compounds as factor XIa inhibitors
EP2867227B1 (en) 2012-06-28 2018-11-21 Novartis AG Complement pathway modulators and uses thereof
EP2867229B1 (en) 2012-06-28 2017-07-26 Novartis AG Pyrrolidine derivatives and their use as complement pathway modulators
US9388199B2 (en) 2012-06-28 2016-07-12 Novartis Ag Pyrrolidine derivatives and their use as complement pathway modulators
CN105121429B (en) 2012-06-28 2017-12-12 诺华股份有限公司 Complement pathway conditioning agent and its purposes
CN104619698B (en) 2012-06-28 2016-08-31 诺华股份有限公司 Pyrrolidin derivatives and the purposes as complement pathway regulator thereof
EP2872503B1 (en) 2012-07-12 2018-06-20 Novartis AG Complement pathway modulators and uses thereof
WO2014059202A1 (en) 2012-10-12 2014-04-17 Bristol-Myers Squibb Company Guanidine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
US9403774B2 (en) 2012-10-12 2016-08-02 Bristol-Myers Squibb Company Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
EA032092B1 (en) 2012-10-12 2019-04-30 Бристол-Майерс Сквибб Компани CRYSTALLINE FORMS OF A FACTOR XIa INHIBITOR
WO2014160668A1 (en) 2013-03-25 2014-10-02 Bristol-Myers Squibb Company Tetrahydroisoquinolines containing substituted azoles as factor xia inhibitors
JP6854126B2 (en) 2013-11-27 2021-04-07 エピックス セラピューティクス Compounds, pharmaceutical compositions, and methods for use in the treatment of inflammatory diseases
EP3988549A1 (en) 2014-01-31 2022-04-27 Bristol-Myers Squibb Company Macrocycles with heterocyclic p2' groups as factor xia inhibitors
NO2760821T3 (en) 2014-01-31 2018-03-10
AP2016009434A0 (en) 2014-02-25 2016-09-30 Achillion Pharmaceuticals Inc Amide compounds for treatment of complement mediated disorders
WO2016036893A1 (en) 2014-09-04 2016-03-10 Bristol-Myers Squibb Company Diamide macrocycles that are fxia inhibitors
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
EP3340983B1 (en) 2015-08-26 2023-10-04 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
AR105809A1 (en) 2015-08-26 2017-11-08 Achillion Pharmaceuticals Inc COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS
AR106018A1 (en) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc ARYL, HETEROARYL AND HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS
WO2017035351A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of medical disorders
WO2017035408A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Compounds for treatment of immune and inflammatory disorders
AR105808A1 (en) 2015-08-26 2017-11-08 Achillion Pharmaceuticals Inc AMIDA COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS
WO2017035361A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Disubstituted compounds for the treatment of medical disorders
WO2017035357A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Phosphonate compounds for treatment of medical disorders
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
WO2017035355A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Ether compounds for treatment of medical disorders
RU2018145364A (en) 2016-06-27 2020-07-28 Ачиллион Фармасьютикалс, Инк. QUINAZOLINE AND INDOLE COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
EP3985002A1 (en) 2017-03-01 2022-04-20 Achillion Pharmaceuticals, Inc. Aryl, heteroary, and heterocyclic pharmaceutical compounds for treatment of medical disorders
ES2933513T3 (en) 2017-03-01 2023-02-09 Achillion Pharmaceuticals Inc Macrocyclic compounds for the treatment of medical disorders
EP3684767B1 (en) 2017-09-22 2024-04-24 Jubilant Epipad LLC Heterocyclic compounds as pad inhibitors
KR20200071752A (en) 2017-10-18 2020-06-19 주빌런트 에피파드 엘엘씨 Imidazo-pyridine compounds as PAD inhibitors
US11629135B2 (en) 2017-11-06 2023-04-18 Jubilant Prodell Llc Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation
SG11202004537UA (en) 2017-11-24 2020-06-29 Jubilant Episcribe Llc Heterocyclic compounds as prmt5 inhibitors
JP7279063B6 (en) 2018-03-13 2024-02-15 ジュビラント プローデル エルエルシー Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation
GB201810486D0 (en) * 2018-06-26 2018-08-08 Imperial Innovations Ltd Natural killer cells
EP3841086A4 (en) 2018-08-20 2022-07-27 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement factor d medical disorders
EP3847174A4 (en) 2018-09-06 2022-06-15 Achillion Pharmaceuticals, Inc. Morphic forms of complement factor d inhibitors
EP3846803A4 (en) 2018-09-06 2022-08-10 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for the treatment of medical disorders
MX2021003425A (en) 2018-09-25 2021-07-16 Achillion Pharmaceuticals Inc Morphic forms of complement factor d inhibitors.
WO2023164238A1 (en) * 2022-02-25 2023-08-31 Regents Of The University Of Minnesota Protease inhibitors

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0215297A2 (en) * 1985-08-14 1987-03-25 G.D. Searle & Co. Substituted dipeptide amides
EP0288965A2 (en) * 1987-04-29 1988-11-02 Hoechst Aktiengesellschaft Peptides with a phospholipase A2 inhibiting activity
EP0337774A2 (en) * 1988-04-12 1989-10-18 Biomeasure, Inc. CCK antagonists
EP0405506A1 (en) * 1989-06-30 1991-01-02 Abbott Laboratories Tetrapeptide type-B CCK receptor ligands
US4997950A (en) * 1989-04-20 1991-03-05 Richard Finbar Murphy Novel C-terminal gastrin antagonists
WO1991012264A1 (en) * 1990-02-09 1991-08-22 Rhone-Poulenc Rorer S.A. N-phenyl n-acetamido glycinamides, preparation method and drugs containing them

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0215297A2 (en) * 1985-08-14 1987-03-25 G.D. Searle & Co. Substituted dipeptide amides
EP0288965A2 (en) * 1987-04-29 1988-11-02 Hoechst Aktiengesellschaft Peptides with a phospholipase A2 inhibiting activity
EP0337774A2 (en) * 1988-04-12 1989-10-18 Biomeasure, Inc. CCK antagonists
US4997950A (en) * 1989-04-20 1991-03-05 Richard Finbar Murphy Novel C-terminal gastrin antagonists
EP0405506A1 (en) * 1989-06-30 1991-01-02 Abbott Laboratories Tetrapeptide type-B CCK receptor ligands
WO1991012264A1 (en) * 1990-02-09 1991-08-22 Rhone-Poulenc Rorer S.A. N-phenyl n-acetamido glycinamides, preparation method and drugs containing them

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J.A.SMITH ET AL 'PEPTIDES,CHEMISTRY AND BIOLOGY; Proceedings 12th American Peptide Symposium, June 16-21, 1991,Cambridge,U.S.A.' 1992 , ESCOM , LEIDEN A.M.NADZAN; "Design of cholecystokinin analogs with high affinity and selectivity for brain CCK receptors" *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107922428A (en) * 2015-06-25 2018-04-17 普洛麦格公司 Thienopyrroles compound and its purposes as the inhibitor for piercing shrimp source property luciferase
CN107922428B (en) * 2015-06-25 2021-02-05 普洛麦格公司 Thienopyrrole compounds and their use as inhibitors of oplophorus-derived luciferase

Also Published As

Publication number Publication date
AU3764593A (en) 1993-11-08
GB9206757D0 (en) 1992-05-13
WO1993020099A2 (en) 1993-10-14

Similar Documents

Publication Publication Date Title
WO1993020099A3 (en) Cck and/or gastrin receptor ligands
EP0703785B8 (en) Methods for treating muscle diseases and disorders
HUP9600596A3 (en) Process for producing pharmaceutical compositions containing rapamycin, for treating cardiac inflammatory disease
CA2204616A1 (en) Ppar gamma antagonists for treating obesity
RU93005168A (en) INDOLINE DERIVATIVES, METHOD FOR PRODUCING THEM, INTERMEDIATE SYNTHESIS COMPOUNDS, USE OF INTERMEDIATE COMPOUNDS AND PHARMACEUTICAL COMPOSITION
EP0403158A3 (en) Imidazolyl-alkenoic acids
CA2274093A1 (en) Substituted pyrimidinone and pyridinone compounds and their use
WO1997020823A3 (en) 2-amino quinazoline derivatives as npy receptor antagonists
EP0201188A3 (en) 5-Substituted pyrazolo[4,3-d] pyrimidine-7-ones, process for preparing the compounds and pharmaceutical compositions comprising the compounds
HUP9900773A3 (en) Use of carbazole derivatives for producing pharmaceutical compositions suitable for the treatment of congestive heart failure
EA199700117A1 (en) TRICYCLIC BENZE-GOLDEN ANTAGONISTS VAZOPRESSIN, METHOD FOR THEIR RECOVERY, PHARMACEUTICAL COMPOSITION AND METHOD OF TREATMENT OF MAMMALS USING Tricyclic Benzene
EP0377272A3 (en) Use of nalmefene or naltrexone in the manufacture of a medicament for the treatment of inflammation in an arthritic disease or associated inflammatory diseases
HUT50445A (en) Process for producing pharmaceutical compositions suitable for preventing sexual diseases
CA2129995A1 (en) Piperidinyl thiacyclic derivatives
IL107134A0 (en) Pharmaceutical compositions for the treatment of parkinson's disease
IL117824A (en) Pharmaceutical compositions containing 2-aryl-imidazol¬1,2-a¾pyridine-3-acetamide derivatives for treatment of neuropsychiatric syndromes associated with dysfunction of the neural circuits of the basal ganglia
MY129173A (en) Novel cyclopentene derivatives useful as antagonists of the motilin receptor
CA2143610A1 (en) Use of norastemizole for the treatment of allergic disorders
ES2054484T3 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING ANTIGEN-ANTIBODY COMPLEXES, AS WELL AS THE USE OF THE SAME.
IT1276167B1 (en) IMIDAZO (1,2-ALPHA) QUINOSSALIN-4-AMINE ACTIVE AS ADENOSINE ANTAGONISTS, PROCEDURE FOR THEIR PREPARATION AND COMPOSITIONS
JPS6470417A (en) Method and composition for treating psoriasis
BG102080A (en) Amino acid derivatives of substituted quinoxalin 2,3-dion derivatives such as glutamate receptor antagonists
ATE45949T1 (en) 4-ALKOXY-PYRIDO(2,3-D>PYRIMIDINE DERIVATIVES, PROCESS FOR THEIR MANUFACTURE AND PHARMACEUTICALS CONTAINING THEM.
DE59010302D1 (en) R - (-) - 1- (5-hydroxyhexyl) -3-methyl-7-propylxanthine, process for its preparation and pharmaceutical compositions containing the same
CA2078869A1 (en) Pharmaceutical compositions containing ipriflavone, process for the preparation thereof and relative therapeutic use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AT AU BB BG BR CA CH CZ DE DK ES FI GB HU JP KP KR KZ LK LU MG MN MW NL NO NZ PL PT RO RU SD SE SK UA US VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

LE32 Later election for international application filed prior to expiration of 19th month from priority date or according to rule 32.2 (b)

Ref country code: KZ

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
LE32 Later election for international application filed prior to expiration of 19th month from priority date or according to rule 32.2 (b)

Ref country code: KZ

AK Designated states

Kind code of ref document: A3

Designated state(s): AT AU BB BG BR CA CH CZ DE DK ES FI GB HU JP KP KR KZ LK LU MG MN MW NL NO NZ PL PT RO RU SD SE SK UA US VN

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i
LE32 Later election for international application filed prior to expiration of 19th month from priority date or according to rule 32.2 (b)

Ref country code: KZ

121 Ep: the epo has been informed by wipo that ep was designated in this application
EX32 Extension under rule 32 effected after completion of technical preparation for international publication

Free format text: BY*,UZ*

LE32 Later election for international application filed prior to expiration of 19th month from priority date or according to rule 32.2 (b)

Free format text: BY*,UZ*

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA